HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.
about
Clinical use and applications of histone deacetylase inhibitors in multiple myelomaTargeting the Mitotic Catastrophe Signaling Pathway in CancerEvaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma modelsIn vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cellsHistone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaA novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells.Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.Entinostat for treatment of solid tumors and hematologic malignancies.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonEntinostat (SNDX-275) for the treatment of non-small cell lung cancer.Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
P2860
Q26745930-BEFEA738-42B2-41BF-BF48-D3C0BA107BB2Q26778544-EB58003F-4D21-4543-91D7-A120D07BEC00Q28817211-98F9113B-2EAF-4232-BDEF-BFA079A46AC0Q33902726-E215D03C-1F9E-4C9B-9B47-A2A98DFD1546Q33934617-ABFBF2B2-59B8-4C09-B031-C488FE11490AQ34511534-E2E00975-730A-4B91-83D5-DD6101FAE89EQ35218534-346E189D-F637-4974-86DC-8084AA3B427BQ35588352-0DEB7778-AA7A-4E1E-8B7A-7BD9CE5E82E2Q35856816-02B96E87-874A-4161-B282-C2BA39D3AD7BQ35915726-491CA83A-D6E5-45D0-8F18-439B487FF88AQ36299600-54F4D4E9-6905-4B48-8124-8A4EBC0DDD8DQ36758025-3C43B2F0-F8EB-41FF-9FBC-BA05E22818EFQ37437269-FA1B5D37-5DF8-4F6B-9414-24D64D514D57Q37672563-33D4AEFE-77F9-4D16-BF18-98464FBF80D9Q37925846-7F27D282-65BF-4DC5-B8C2-FCF49479EB2BQ38161731-A30B9B76-F1D0-4B38-801F-C9C44C70422FQ38478630-DBD27522-CDA8-4DCD-A305-3FB52C0BA46EQ38534163-C1FF2FDF-FDA4-407D-9816-813883B5E601Q38896751-2F78D16C-FD9B-4DA5-84AE-874A0455BC74Q39048347-AB8AF189-887C-451E-9630-89A8ADCD2DA0Q39185574-FF5A61B8-E07F-45CB-A8EA-2CC8154A00BBQ39525805-3EA82CF4-36F7-448D-AC08-50CE64F4900AQ39954100-9F166763-8ABE-4776-A0E7-092BBC1AFDC2Q42459032-EEB14503-6CC2-4AC2-B0F7-55CC0C5F1639Q43103345-2046DBC4-8DD3-43F3-9B3E-B61EF981A7FEQ46316392-3AB98C5F-4DDF-48B0-97F2-01DF71FF092C
P2860
HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@en
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@nl
type
label
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@en
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@nl
prefLabel
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@en
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@nl
P2093
P2860
P1433
P1476
HDAC inhibition synergisticall ...... sis in multiple myeloma cells.
@en
P2093
Choon-Kee Lee
John Ryder
Shuiliang Wang
Xiaoping Huang
P2860
P304
P356
10.1016/J.CANLET.2010.04.014
P407
P50
P577
2010-05-05T00:00:00Z